CDKN2A and neoplasm: In explorative analyses in p16- patients to identify prognostic factors for OS low age (≤65 years) (HR: 0.51, 95% CI: 0.14–1.78; p = 0.036), lower tumor stage (HR: 0.16, 95% CI: 0.05–0.53; p = 0.007) and treatment schedule A or B (HR: 0, p = 0.009; Table 4) were associated with favorable outcome.